{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-017288","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.252563+00:00","generated_at":"2026-05-18T09:58:47.596285+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Processa Pharmaceuticals Announces Strategic Portfolio Review, Pipeline Realignment, and $7M Capital Infusion","bullets":["Terminated licensing agreement with Ocuphire Pharma (now Opus Genetics) for PCS3117, returning rights to original licensor.","Signed binding term sheet with Intact Therapeutics granting exclusive option to license PCS12852; eligible for up to $454M milestones and 12% royalty.","Continues enrolling patients in Phase 2 study of PCS6422 (NGC-Cap) for metastatic breast cancer; interim data expected H2 2025.","Strengthened balance sheet with $7 million capital infusion.","Establishing dedicated subsidiary for PCS499; designing new adaptive pivotal Phase III study for rare kidney disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-017288","json":"https://secwatch.observer/filing/0001641172-25-017288.json","markdown":"https://secwatch.observer/filing/0001641172-25-017288.md","text":"https://secwatch.observer/filing/0001641172-25-017288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000164117225017288/0001641172-25-017288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000164117225017288/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-18T09:58:47.596285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}